Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review

Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review

Introduction: Encorafenib and binimetinib, a combination of BRAF and MEK inhibitors, is a standard of care for patients with advanced BRAFV600-mutant melanoma. This combination is known to have gastrointestinal side effects, most of which are mild and managed symptomatically. However, very few studi...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Chloe Wautier, Jolanta Gourmaud, Catherine Dong, Gregoire Berthod
Formaat: Artikel
Taal:English
Gepubliceerd in: Karger Publishers 2024-02-01
Reeks:Case Reports in Oncology
Onderwerpen:
colitis
gastrointestinal toxicity
melanoma
encorafenib
binimetinib
Online toegang:https://beta.karger.com/Article/FullText/535741

Internet

https://beta.karger.com/Article/FullText/535741

Gelijkaardige items